

Subject Index

Note: Page references followed by f and t indicate an illustrated figure and table, respectively.

- AARP members, impact 149
- Acceleration (operations) 7
- Accounting 31–32
 - advocacy 240
 - bottom line 116–117
 - complexity 61
 - fighting 223–224
 - mitigation 221–222
 - reasons 222
 - complication 61–62
 - contribution, trivialization 46–47
 - decline 81
 - defense 70
 - estimates
 - domination 95–96
 - impact 98–100
 - increase 100–101
 - problems 79
 - proliferation, reversal 219–221
 - reliability, enhancement 98
 - events 105–107
 - expenses, breakdown (usage) 175–176
 - facts 94
 - absence 79
 - fairness 35–36
 - fault 50
 - fiction 94
 - graveyards 86
 - impact, intention 17–18
 - information (usefulness loss), investor interest 68–70
 - link, absence 104–105
 - losses 57–58
 - procedures, structure (impact) 35
 - recognition, delay 105–106
 - records, triggers 79–80
 - reform agenda 213
 - regulations, proliferation 56–57
 - relevance
 - decrease 37, 41, 89f
 - loss 38–90
 - reporting, direction (change) 214
 - revitalization 213–214
 - ROE 22
 - rules, change (demand) 90
 - Strategic Resources & Consequences Report issue 197
 - treatment. *See* Intangible assets.
 - uncertainty/vagueness, example 94–95
 - usefulness, quest 62
- Accounts receivable 96
- Acquired intangibles, certainty 84
- Adjusted coefficient of variation (R^2) 33, 89, 108
- Affordable Health Care Act (Obamacare) 221
- Agent-driven policies 152
- Agents, importance 152–153
- All-in sustaining costs (AISC) 204
- Allstate
 - advertising campaign 155
 - Drive Wise car device 152
 - online customers 156
 - rate-increasing policy 151
- Alphabet (Google) 120
- Amazon, patents 78

- Ambiguity, increase 68–69
- American Airlines, balance sheet 87
- Amgen, Inc.
market share data, inconsistency 169
sales 169
- Amortization 95
estimate 79
- Analyst forecasts 45, 46f
performance-related information
source 44
release 46–47
- Analysts
ambiguity, increase 64f
guidance 15–17
impact 62
pipeline questions, Pfizer response
200–201
pipeline-related questions,
number/percentage 202f
questions 114–115
- Annual earnings releases 44
- Annual report, extensiveness 5
- Apple
brand, value 234
car streaming market 140
patents 78
problem 90
- Arm's-length transactions 83–84
- Assets
amortization 216–217
conceptual assets 82
deployment, outcomes 125
fair valuation 37–38
fair values 61
obsolescence 124
real assets 82
recognition 78
treatment (intangible assets) 214–217
write-downs 109
write-offs 37, 97
- AstraZeneca 166
Actavis acquisition 164
drug extension 174
stock price loss 104–105
- Auden McKenzie 164
- Bad debt expense 220
- Bad-debt reserve 79
- Balance sheet 4, 5
corporate balance sheets, recognition
78
distortion 37
usage 7
- Bayer, brand (value) 234
- Berkshire Hathaway 153
- Beta tests 105
- Biotech, Strategic Resources &
Consequences Report 163
- Blackberry patents, problem 90
- Blue Book 97
- Boeing, innovation strategies 85
- Book-to-bill ratio 204
- Book value
impact 31f
investor usage 32–33
problems 34–35
regression 89f
relevance-loss 34–35
share 35f
- Book value of equity (BV) 38
- Bottom line 116–117
- Brands 234
creation 134
development 153
enhancement 175
- British Petroleum (BP)
household name 180
problems 189
- Buffett, Warren 37, 53, 97, 153
- Build-to-order business model 232
- Businesses
enterprises
evolution 53
long-term objective 119–120
failure 90
fundamentals 58
organization, change 6–7
processes 78, 83
IT support 122–123
volatility, decrease 71–73
- BV. *See* Book value of equity

- Capitalization 89
- Capital lease 222
- Capital market-free test 67
- Cash burn rate 175
- Cash flows
 - analyst prediction 24f
 - concept, accounting impact (intention) 17–18
 - earnings, domination 18–19
 - metric 17
 - prediction, ease 22–24
 - increase 23f
 - residual cash flows, usage 238f
 - statement 5
 - strategies, earnings (contrast) 19f
- Cash flows per share (CPS) 23–24
- Causal factors 231–232
- Causation, examination 107–108
- Cease and desist agreement 174
- China National Petroleum, household name 180
- Cisco, stockholder equity 126
- Claims expenses 154
- Coca-Cola
 - assets 83
 - consumer product business 88
 - patents 78
- Combined ratio 148
 - increase 150–151
- Commission, sins 104
- Commodities 78
- Communication theory (information theory) 42
- Companies
 - balance sheet, inventory account 233
 - company-related information sources 44
 - earnings
 - investor reaction 30–31
 - prediction 16f
 - 8-K filings 106–107
 - estimates (above-median number), ROE prediction errors (increase) 101f
 - market values 32–33
 - differences 33
 - patents
 - information 171, 173
 - portfolios 218
 - performance prediction, ability (decline) 56–57
 - prospects, uncertainty (decrease) 65
 - trademarks, information 171, 173
- Comparability 203
- Competition
 - enhancement 134
 - implementation concerns 205–206
- Competitive advantage, achievement 120–121, 134
- Competitive edge, assessment 232
- Complexity. *See* Accounting
- Compustat data 23–24, 48
- Conceptual assets 82
- Conceptual industries 37
- Consensus earnings estimate, missing/beating (consequences) 21f
- Consensus estimate 15, 16
- Consequences report 126–129
- Conservatism bias, manifestation 109
- Conservatism principle 108–109
- Conservative accountants, examination 108–110
- Conspiracy of silence, application 86
- Consumer demand, shifts 72
- Content creation 129
- Control systems 72
- Corporate acquisitions 96
- Corporate balance sheets, recognition 78
- Corporate disclosure, elicitation 203
- Corporate earnings
 - prediction 53–54
 - investment mechanism 16
 - reporting 21–22
- Corporate financial disclosure, industry associations (impact) 204
- Corporate financial information
 - domination 70
 - relevance 31–32
 - system, complexity 221
- Corporate financial reporting, apogee 7

- Corporate financial reports
 - future 52–53
 - information content, capture process 32
- Corporate growth 82
- Corporate managers, short-term results (delivery) 207
- Corporate market value
 - book value, impact (share) 35f
 - decrease, meaning 33–34
 - earnings/book value, impact 31f
 - financial indicators, impact (share) 36f
 - impact, share 34f
- Corporate mission 119–120
- Corporate operations, rejuvenation 108
- Corporate performance (evaluation), consensus estimate (usage) 15
- Corporate reporting 1
 - differences 1–4
 - observation 4–5
 - improvements 5–7
- Corporate reports
 - estimate-related terms 98
- Corporate sales, volatility (decrease) 72f
- Corporate SEC filings, performance-related information source 44
- Corporate strategy, change 6–7
- Corporate value 82
 - nontransactional business events, impact 79–80
 - unrecorded events, impact 79–80
- Costs, examination 155–157
- CRSP data 23–24
- Customers
 - acquisitions cost 134
 - ROI 129
 - benefit, enterprise (long-term survival) 119
 - box, example 150f
 - configure-to-order features 232
 - franchise 233
 - management, balancing 149
 - non-GAAP customer information 137
 - satisfaction 52
 - Strategic Resources & Consequences Report 149–151
- Decision relevance 67
- Deferred revenue 223
- Depreciation 95, 192
 - estimate 79
- Development risk diversification 171
- Devon Energy Corp.
 - footprint size 187
 - location-specific disclosure 183
 - mineral acreage 185, 187
 - reserve life index 187
 - strategy, articulation 182
- Disclosure
 - improvement 217–219
 - proposal, endorsement 203
 - requirement 181
- Dispersion (variation) 64
- Disruption 123
 - cheat 140
- Dodd-Frank Wall Street Reform and Consumer Protection Act 221
- Double-entry bookkeeping 113
- Drugs, development 171
- Dynamic portfolio management 180, 181
- Eagle Ford assets, acquisition 182
- Earnings 15
 - analyst forecast, corporate manager role 15–16
 - analyst prediction 24f
 - cash flows
 - strategies, contrast 19f
 - substitution 17–18
 - consensus 20–21
 - earnings estimate, missing/beating (consequences) 21f
 - misses 20
 - corporate market value, impact (share) 34f
 - decline 109
 - domination, cessation 18–19
 - estimates, dispersion/variation 64

- forecast models, inputs 15
- future earnings (prediction), earnings
 - reporting ability (decline) 55f
- impact 31f
- improvement 17
- informativeness, mitigation 220
- investor usage 32–33
- management 20–21
 - manipulation 63
- manipulations 119–120
- prediction 15–17, 23f
- prediction, ease 22–24
- prediction error
 - cash flow, comparison 22–23
 - computation 23
 - nonaccounting events, impact 107f
- problems 34–35
- relevance-loss 34–35
- reported earnings, release 46
- reporting ability, decline 55f
 - reasons 56–67
- strategy, results 19
- transitory items, impact (increase) 57f
- updating 17
- usefulness 101
 - assessment 54
 - deterioration, evidence 55
- Earnings before expenses (EBE) 205
- Earnings per share (EPS) 43, 94
 - enhancement 119
 - forecasts 64
 - reports 47
- EBE. *See* Earnings before expenses
- EBITDA multiple, impact 182
- Economic profits 120
- Economic turbulence/volatility, increase (perception) 71
- Economy-at-large 72
- Efforts/achievements, integrated system 127, 129
- Employee pensions, basis 79
- Employee stock options 109
 - expense 96
- Employee training, investment 86–87
- Enterprise performance, assessment 232
- Enterprises, long-term survival 119
- Equity capital, cost 175
- Equity position 180–181
- Estimate-related dictionary 98
- Estimate-related expressions, proxy 101
- Estimate-related terms 98
 - frequency, increase 99f, 100–101
- Estimates. *See* Accounting
 - above-median number, ROE
 - prediction errors (increase) 101f
 - domination 95–96
 - managerial estimates, proliferation 38
 - verification, enabling 220–221
- Esurance 148, 151, 156
- European Union (EU), regulatory agency (absence) 221
- Excess-of-loss clause 158
- Extraordinary items, amount (increase) 100f
- Exxon
 - analyst questions 116, 120
 - earnings, increase 53–54
 - household name 180
 - investment 53
 - M&A strategy 115–116
 - net income 52
 - production guide 190–191
 - questions 115–116
 - Valdez, oil spill 52
- Facebook, IPO 51
- Fair value 97
- FASB. *See* Financial Accounting Standards Board
- Field, Marshall 4
- Financial Accounting Standards Board (FASB) 6, 18, 181, 222
 - regulatory record, examination 213–214
- Financial capital 82
- Financial crisis, real estate (depression) 32–33
- Financial data
 - estimates 124
 - relevance, decrease 36
- Financial indicators, impact (share) 36f

- Financial information
 - basis, problems 35–36
 - damage, accounting/nonaccounting (impact) 90
 - deterioration, accounting estimates (impact) 98–100
 - interpretation, experts (usage) 62
 - irrelevance 37
 - market, competition 41–42
 - quality 68
 - role 37
 - stock prices, contrast 29
 - usefulness
 - decline 56, 67–68, 206
 - loss, investor interest 68–70
 - measurement 29–31
- Financial innovations 71
- Financial reporting
 - direction, change 214
 - purpose (FASB) 30
- Financial reports 46f
 - contextual role 47
 - contribution 47
 - estimation, statistical methodology (usage) 44–45
 - economic condition 62
 - estimate-related terms, frequency (increase) 99f
 - indicators, role 67
 - opaqueness 86–87
 - performance 62
 - performance-related information
 - source 44
 - structure, freezing 8
 - structure/information, similarity 2
 - timelines, measurement 43–45
- Firm operations, bottom line 154
- Firm-specific errors 54
- First-in-class product (Pfizer) 169–170
- Follow-on patenting 166
- Footprint size 187
- Ford, Henry 52, 116
- Ford Motor Company, car production 1
- Forecasts, verification (enabling) 220–221
- Fortune Global 500 Companies*, 180
- Full revelation, economic principle 202
- Fundamentals 51
- Funds
 - decrease 69–70
 - sources 32
 - uses 32
- Future earnings (prediction), earnings reporting ability (decline) 55f
- Geico
 - advertising 147
 - brand, re-creation (impossibility) 148
- General Electric, earnings per share (EPS) uncertainty/vagueness 94–95
- Generally accepted accounting principles (GAAP) 96, 115
 - information 204
 - mandate 217
 - non-GAAP customer information 137
 - non-GAAP disclosure, problem 169
 - non-GAAP earnings, merits 205
 - non-GAAP measure 176
 - reforming 218
 - ROE 216
 - total sales, relevance (limitation) 174–175
- Gilead, product pipeline 170–171
- Goldman Sachs, investment dominance 83
- Goodwill 109
 - GAAP mandate 217
 - value, impairment 61
 - write-offs 96, 219
- Google
 - car streaming market 140
 - intangible investment, increase 85
- Great Depression 71
- Great Moderation 71
- Gross Domestic Product (GDP) growth 232
- Gross margin ratio 154
- Hedge fund managers, returns 17
- Hewlett-Packard, Autonomy acquisition 84
- Historical values 96–98

- Human capital, development 86–87
Hurricane Sandy claims 158
- I/B/E/S data 23–24
 First Call 48
- IBM
 shares, decline 20
 turnaround 122
- IFRS. *See* International Financial Reporting Standard
- Implementation
 competition/litigation concerns 205–206
 industry associations, impact 204
 manager cooperation 204–205
 regulatory burden, lightening 206–208
 SEC role 203
 Strategic Resources & Consequences Report issue 197, 199
- Income statement 5
 distortion 37
 usage 7
- Industry associations, impact 204
- Industry-specific strategic resources 129
- Industry-specific technological disruptions 71–72
- In-force policies 152
- Information. *See* Financial information
 backward-looking information 52
 company-related information sources 44
 competition/litigation concerns 205–206
 contribution 44
 disagreement 63
 quantification 63–65
 importance 42
 increase, requirement 87–88
 intermediaries 62
 manager cooperation 204–205
 problems 84–86
 proposed information, elicitation process 199–200
 regulatory burden, lightening 206–208
 SEC role 203
 sources 68–69
 alternative 70
 ranking 30
 theory (communication theory) 42
 timelines, issue 43
 uniformity 169
 usefulness, measurement 30
 uselessness 32
 vagueness 63
- Infringement 123
- In-line products box 169–170
- Innovation 166, 168
 disruption 123
 financial innovations 74
 investment 164–165
 revenues 176
- In-process-R&D (IPRD) 96
 balance sheet value 97
- Insurance
 company operations 154f
 operations, risk 158
- Intangible assets
 accounting
 problems 83–84
 relevance, loss 88–90
 rules, change (demand) 90
 treatment 77–78
 acquisition 85–86
 amortization 216
 asset treatment 214–217
 capitalization 216
 conspiracy of silence, application 86
 disclosure, improvement 217–219
 economic role, increase 37
 emergence 37–38
 increase 81–83
 information
 increase, requirement 87–88
 problems 84–86
 investment, Google increase 85
 nontradability 87–88
 revolution 82f
 treatment, problem 78
 uniqueness 87–88
 valuation 215

- Intangible capital
 - increase 83
 - U.S. private sector investment 82f
- Intangible investments, expensing 216
- Intellectual assets, economic role (increase) 37
- Intellectual capital reports 113
- Internal controls, gross inadequacies 123–124
- International Financial Reporting Standard (IFRS) 217
- Internet chat rooms 7
- Internet service providers, patents 234
- Inventory
 - account 233
 - contribution 78
 - improvement 72
 - taking 233–235
- Investments 156
 - efficiency 122
 - mapping 121–123
 - returns 18–19
 - risk, diversification 158
- Investors
 - agreement 63
 - contribution, example 45–46
 - decisions
 - erosion 37–38
 - reported financial information, role 37
 - triggering 30
 - disagreement 63
 - fault 50
 - importance 119
 - information
 - contribution 46f
 - demand, SEC role 203
 - needs 114
 - relevance 185
 - investor-relevant information system 159
 - irrationality 50–51
 - necessity 142–144
 - operating instructions, Strategic Resources & Consequences Report issue 197, 230
 - reaction, measurement 43–44
 - usefulness 122
 - valuation process 219–220
- IPRD. *See* In-process-R&D
- Irrational investors 50–51
- Jobs, Steve 52
- Johnson, Don 31
- Johnson & Johnson's
 - operations cash 165
 - Pfizer, comparison 165
- Joint relevance-loss of earnings, problem 34–35
- Joint ventures 86
 - rarity 7
 - ROI, assessment 138
- Just-in-time strategy 7
- Key performance indicators (KPIs) 113, 127
 - lists, disparateness 129
- Knowledge economy 78
- KYTHERA Biopharmaceuticals 164, 166
- Lease capitalization, avoidance 222
- Liabilities
 - fair valuation 37–38
 - fair values 61
- Liber Abaci* (Fibonacci) 231
- Life and health (LH) 147
- Limited liability corporation, establishment 95–96
- Litigation
 - implementation concerns 205–206
 - risk 90
- Lockheed Martin, innovation strategies 85
- Lundholm, Russell 220–221
- Management Discussion and Analysis (MD&A) section 5
- Management, risk mitigation strategies 159
- Managerial estimates, proliferation 38

- Managers
 competitive concerns 129
 decisions, distortions 85–86
 estimates/forecasts
 proliferation 219
 verification, enabling 220–221
 forecasts 47
 performance-related information
 source 44
 guidance 116
 importance 119
 wishful thinking 205
- Marked-to-market items 97
- Marked-to-myth 37, 97
- Market share, loss 173
- Markets, movement
 absence 19
 earnings, impact 57
- Market value (MV) 32–33, 38
 capitalization 89
 regression 89f
- Mark to market nontraded
 assets/liabilities 37–38
- Media/entertainment, Strategic
 Resources & Consequences Report
 133–135, 143f
- Medical costs, inflation (impact)
 155–156
- Medical devices, development 171
- Merck
 joint development 168
 Q3–2013 sales, decrease 174–175
- Mergers and acquisitions (M&A) 96
- Message, information 41–43
- Metacloud Technology 216–217
- Momentum (operations) 7
- Monetary information 127
- Morgan, J. Pierpont 4, 5
- MV. *See* Market value
- National Income Accounts 215
- Near facts 220
- Nestea 88
- Netflix
 analyst questions 114–115, 120
 customer recommendation
 algorithms 121
 services 115
 strategic assets 115
- Net income (NI)
 extraordinary/special items, increase
 100f
 report 38
- New products, innovation 151–152
- NI. *See* Net income
- Nonaccounting
 data, presentation 144
 events 105–107
 frequency/impact, increase 106f
 impact 90, 107f
 SEC filings 46f
- Noncoercive disclosure initiative,
 manager cooperation 204–205
- Nonfinancial S&P 500 companies,
 focus 69
- Non-GAAP customer information 137
- Non-GAAP disclosure 204–205
 problem 169
- Non-GAAP earnings, merits 205
- Nontraded assets/liabilities,
 marking-to-market 219
- Nontransactional business events,
 impact 79–80
- Number of shares outstanding
 (NSH) 38
- Occam's razor 232
- Off-balance-sheet financing 61
- Oil/gas companies, Strategic Resources
 & Consequences Report 179, 193f
 accounting limitations 180–181
 operations, sensitivity 190
 reserve-replacement ratio 191
 resource deployment, operations
 190–192, 191f
 resource investments 181–185
 example 184f
 resources, threats 188–190
 risk 189–190
 strategic resources 185–188
 example 186f
 value creation 192

- Omission, sins 104
- One-time items 56–57
- On-the-market drug portfolio, sustainability 233
- Operating analysis 155
- Operating expenses 154, 156
- Operating strategic assets 233
- Operations
 - acceleration/momentum 7
 - sensitivity 190
- Operations, resource deployment 153–155
- Organizational capital 78
- Organizational knowledge, accumulation 124
- Patents 78, 83, 234
 - classification 171, 173
 - expiration 174, 235
 - follow-on patenting 166
 - Pfizer acquisition 84–85
 - portfolios 218
 - problem 90
- Path dependence 52, 53
- PC. *See* Property and casualty
- PCAOB. *See* Public Company Accounting Oversight Board
- Penetration gains 139
- Pepsi 88
- Performance measures, annual median absolute prediction error 54–55
- Pfizer
 - company strategy 164
 - competitors 120
 - credit, enhanced transparency 202
 - drug launch 169–170
 - earnings conference calls, Q&A section 201
 - expected financials, earnings conference call 16
 - FDA decisions, impact 200
 - first-in-class product 169–170
 - growth prospects 78
 - Johnson & Johnson's, comparison 165
 - joint development 168
 - patents 78, 88
 - pipeline-related questions, number/percentage 202f
 - product pipeline, 10-K disclosure enhancements 209t
 - R&D expenses 165
 - response (analyst pipeline questions) 200–201
 - restructuring cost 108
 - ROE 84–85
 - sales, expiration 164–165
 - 10-K filings 200–201
 - transparency, enhancement 202
- Pharmaceuticals, Strategic Resources & Consequences Report 163, 167f
- Physical capital 82
- Pipeline
 - exposé, reasons 201–203
 - pipeline-related questions, number/percentage 202f
 - questions, Pfizer response 200–201
 - test data, usefulness 170–171
- Policies-in-force data 150
- Post-financial crisis 19
- Premium prices, charging 234
- Price to earnings ratio (P/E ratio) 53, 232
- Procter & Gamble, consumer product business 88
- Product pipeline 170–173, 233
 - candidates 172f
 - enhancements 209t
- Products
 - growth 139
 - launch 105
- Profitability
 - maintenance 150–151
 - measures 78
 - ratios, inflation 216
- Progressive
 - advertising 147
 - year-on-year revenue growth reports 157
- Property and casualty (PC) business risk 147

- Property and casualty (PC) firms,
 dominance 147
- Property and casualty (PC) insurance,
 Strategic Resources &
 Consequences Report 146, 160f
 sector synopsis 147–148
- Proposed information, elicitation
 process 199–200
- Prosensa Holding NV, drug failure 104
- Public companies
 financial analyst tracking 63
 vintage year, accounting relevance
 (decrease) 89f
- Public Company Accounting Oversight
 Board (PCAOB), enforcement
 actions 56
- Quantitative easing 32–33
 Fed termination 54
- Quarterly buy-and-hold abnormal
 return 47–48
- Quarterly earnings releases 44
- Quarterly reporting, elimination
 (consideration) 207
- R^2 . *See* Adjusted coefficient of variation
- Real assets 82
- Real estate sales, turnover 97
- Regression analysis, example 33–34
- Regulation Fair Disclosure 45
- Regulatory burden, lightening 206–208
- Regulatory risk 158
- Reinsurance 147
- Reinsurers, company exposure 153
- Relevance, loss 77
- Reported earnings
 components 149
 release 46
 understatement 216
- Reported financial information, role
 (documentation) 37–38
- Reporting. *See* Corporate reporting
 consequences 138
 frequency 208
- Reports, information (uselessness) 32
- Research and development (R&D)
 84–85, 120
 accounting 214–215
 capitalization 217
 decrease 85
 expenditures 122
 in-process-R&D 96
 program 83
 total expenditure 86
- Reserve life index 187
- Reserve-replacement ratio 191
- Residual cash flows, usage 238f
- Resource-based theory 121
- Resource prices 71
 changes 71–72
- Resources. *See* Strategic resources
 deployment 153–155
 operations 174–175, 190–192,
 191f
 investments 181–185
 example 184f
 mapping 121–123
 Strategic Resources &
 Consequences Report 165–166
 preservation 157–159, 173–174
 threats 188–190
- Restructuring cost 108
- Retention percentage 58
- Return on assets (ROA) 78
- Return on equity (ROE) 78
 increase 84–85
 metric 54–55
 prediction
 demonstration 55
 errors 101f
- Return on income (ROI) 129
- Revealed preferences 200
- Revenues
 accounting 223
 deferred revenue 223
 innovation revenues 176
 matching 109
 recognition rules 223
 revenue-cost mismatch, occurrence
 215
- Reverse-engineering 124

- Richels, John 182
- Risk
- development risk diversification 171
 - hedging 71
 - insurer purchases 158
 - management 153
 - mitigation strategies 159
 - similarity 64
 - types 158
- Risky assets, managerial presentation 90
- Roche, royalties 170
- Rockefeller, John D. 4, 5, 52
- Roosevelt, Theodore 1
- Royal Bank of Scotland (RBS), restructuring cost (expectation) 108
- Royal Dutch Shell
- earnings 181–182
 - household name 180
 - Q3–2012 call 183
- Sales, general, and administrative (SG&A) 122, 218
- curve 89–90
 - expenses 36, 39, 67, 86
- Sales, prediction 15–16
- Same-store sales 190
- Sarbanes-Oxley Act (2002) 123–124
- Sarepta Therapeutics, Inc., stock increase 104–105
- Schlumberger, SPM arrangement 180–181
- Schwab, Charles M. 4
- Science-based providers, patents 234
- Sector synopsis 134–135
- Securities Act (1933–1934), 29–30
- Securities analysis, focus 231–232
- Securities and Exchange Commission (SEC)
- enforcement actions 56
 - filings 48
 - nonaccounting filings 45
 - Regulation Fair Disclosure 45
 - regulations/enforcement actions 30
- Security Analysis* (Graham) 53
- Segment report, informativeness 6
- Sell-side financial analysts 62
- Services, launch 105
- SFAS No. 2 1974, 214–215
- Shareholders
- trust 52
 - value, detracting 219
- Share prices, informativeness (decline) 69
- Short-term earnings, increase 122
- Short-term investments, contribution 78
- Sirius XM
- disruption threat 140
 - operation, quality 142
- Strategic Resources & Consequences Report 135, 136f
- reality 141–142
 - strategy 138–140
 - subscribers
 - franchise, lifetime value 141
 - growth 135–138
- Snapshot 148
- Southwest Airlines, business processes 78
- Special items, amount (increase) 100f
- Special-purpose entities 61
- Standard & Poor's 500 Index, benchmark return 22
- Standard & Poor's Insurance Select Industry Index 147
- Standard & Poor's SEC Filings Database 48
- Starbucks, brand (value) 234
- Stock prices
- correlation 42–43
 - financial information
 - contrast 29
 - link, deterioration 51
- information 69
- Stocks
- options expenses 79
 - risk 158
- Strategic assets
- creation/maintenance 235–236
 - deployment 124–125, 236–237
 - operating strategic assets 233

- operation 124–125
- portfolio, maintenance 235–236
- usage 148–149
- Strategic resources 120, 121, 164
 - inventory, taking 233–235
 - investments, considerations 175
 - oil/gas companies 185–188
 - pharmaceutics/biotech 168–173
 - preservation/renewal 123–124
 - proposal 126–129
- Strategic Resources & Consequences Report
 - agents, importance 152–153
 - customers 149–151
 - example 128f
 - innovation 166, 168
 - investment 164–165
 - investors
 - necessity 142–144
 - operating instructions 197, 230
 - media/entertainment, Case No. 1, 133, 143f
 - sector synopsis 134–135
 - Sirius XM 135–140
 - new products, innovation 151–152
 - oil/gas companies, Case No. 4, 179, 193f
 - accounting limitations 180–181
 - resource deployment, operations 190–192, 191f
 - resource investments 181–185
 - resource investments, example 184f
 - resources, threats 188–190
 - strategic resources 185–188
 - strategic resources, example 186f
 - value creation 192
 - operations, resource deployment 153–155
 - pharmaceutics/biotech, Case No. 3, 163, 167f
 - in-line products box 169–170
 - market share, loss 173
 - patent expirations 174
 - product pipeline 170–173
 - product pipeline, candidates 172f
 - regulatory changes 174
 - resource deployment operations 174–175
 - resource preservation 173–174
 - strategic resources 164, 168–173
 - strategy 164
 - value creation 175–176
 - property/casualty insurance, Case No. 2, 146, 160
 - insurance company operations 154f
 - sector synopsis 147–148
 - resource investments 165–166
 - Sirius XM 135–138, 136f
 - value creation 140–141
- Strategic transparency 120
- Strategy 164
 - articulation 138
- Subscription-based enterprises, returns 144
- Summa arithmetica, Geometria, Proportioni, et Proportionalitas* (Pacioli) 105
- Summary measures 32
- Sustained competitive advantage 119–120
- Symptoms, focus 231–232
- Talent, uniqueness 234
- Tangible capital, U.S. private sector investment 82f
- Technological feasibility 105
- Technology
 - improvement 7
 - providers, patents 234
- Total claim payments, GAAP 156
- Total periodic expenditure 218
- Total sales
 - equivalence 7
 - M&A effect, impact 175
- Trademarks, information 171–172
- Trading strategy, computation 22
- Transactions
 - impact 79–80
 - third-party transactions 105–106
- Transitory items, impact (increase) 57f
- Transparency, enhancement 202

- Triple bottom line 113
Triple entry bookkeeping 7
- Uncertainty, increase 68–69
Uncollectible receivables 220
Underwriting
 cycles 149
 risk 158
United States corporate investment,
 pattern 81–82
United States Patent Office (USPO),
 patent classification 171, 173
United States Steel Corporation
 annual report, publication 1
 balance sheet (1902) 10f–11f
 cash flow statement, requirement
 (absence) 4
 consolidated balance sheet 3t
 consolidated income statement 2t
 financial operations, summary 12f
 footnote section, example 6
 growth, internal generation (founder
 belief) 4
 loss 4
 profit and loss statement (1902) 9f
 reports
 differences 6
 risk/litigation/environment issues,
 discussion 5
 segment report, informativeness 6
- Unrecognized business events, increase
 107
Unrecorded events, impact (increase)
 79–80
Used-car market 139
- Value creation
 intangibles, impact 82–83
 measurement 125–126
 differences 126
 media/entertainment 140–141
 oil/gas companies 192
 pharmaceuticals/biotech 175–176
 property/casualty insurance 159–160
 vehicle 83
Verizon, results (announcement) 43
Volatility 71
 decline, acceleration 72
 decrease. *See* Businesses; Corporate
 sales.
 turbulence 72–73
- Wal-Mart, business processes 78
Warranties provisions 220
Workforce employment 119
World Gold Council, working group
 formation 204
- XBRL 7
Xerox, brand (value) 234

<http://www.pbookshop.com>

<http://www.pbookshop.com>